|  |
| --- |
| **Supplementary Table 3. Baseline characteristics of sub-cohort of new metformin users** |
| **Characteristic**  | **All participants (n=2,911,051)****Number (%)** | **Metformin users (n=264,641)****Number (%)** | **Non-users of metformin (n=2,646,410)****Number (%)** |
|
| Age, mean years (SD) | 56.1 (±13.7) | 56.1 (±13.7) | 56.1 (±13.7) |
| Sex |  |  |  |  |
|  | Men | 1,712,315 (58.8) | 155,665 (58.8) | 1,556,650 (58.8) |
|  | Women | 1,198,736 (41.2) | 108,976 (41.2) | 1,089,760 (41.2) |
| Residence in Sweden |  |  |  |
|  | Eastern/Southern | 2,332,627 (80.1) | 208,846 (79.0) | 2,123,781 (80.3) |
|  | Northern | 570,463 (19.6) | 55,438 (21.0) | 515,025 (19.5) |
|  | Unknown | 7,961 (0.3) | 357 (0.1) | 7,604 (0.3) |
| Smoking a |  | 67,660 (2.3) | 7,924 (3.0) | 59,736 (2.3) |
| Alcohol overconsumption a | 72,507 (2.5) | 7,490 (2.8) | 65,017 (2.5) |
| Use of NSAIDs or aspirin | 913,244 (31.4) | 113,946 (43.1) | 799,298 (30.2) |
| Use of statins | 612,684 (21.1) | 135,902 (51.4) | 476,782 (18.0) |
| Duration of follow-up, mean years (SD) | 4.4 (±2.7) | 4.4 (±2.7) | 4.4 (±2.7) |
| ESCC cases |  | 636 (0.02) | 37 (0.01) | 599 (0.02) |
| ESCC Incidence per 100,000 person-years (95% CI) | 5.0 (4.6-5.4) | 3.2 (2.3-4.4) | 5.2 (4.8-5.6) |
| Death during follow-up | 220,131 (7.6) | 25,548 (9.7) | 194,583 (7.4) |
| a Assessed within the ten years before study entry |
| Abbreviations: ESCC=esophageal squamous cell carcinoma, NSAIDs= non-steroidal anti-inflammatory drugs, SD=standard deviation, CI=confidence interval |
|  |